Description:
LDE225 (NVP-LDE225) is potent antagonist of SMO (smoothened). This small molecule compound is a hedgehog pathway inhibitor by directly inding to SMO. This molecule has been developed by the Novartis harma for clinical application against hedgehog-dependent cancers.
Ref: S Pan et al. Discovery of NVP-LDE225, a Potent and Selective SmoothenedAntagonist. ACS Med. Chem. Lett., 2010, 1 (3), pp 130–134
Biological Activity:
In a cell-based assay measuring the activation of the Gli-1 reporter gene,this compound gives IC50 of 15-40 nM.
